Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

By Bonafede Machaon   Joseph George J.   Princic Nicole   Harrison David J.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1120-1128

Informa Healthcare

Access to resources Recommend Favorite

A narrative literature review of the impact of anti-TNFα treatment on the occupational performance of people with rheumatoid arthritis or ankylosing spondylitis

By McArthur Margaret   Birt Linda   Goodacre Lynne  

The British Journal of Occupational Therapy, Vol. 76, Iss. 10, 2013-10 ,pp. : 456-469

College of Occupational Therapists

Access to resources Recommend Favorite

Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis

By Confavreux C.   Chapurlat R.  

Osteoporosis International, Vol. 22, Iss. 4, 2011-04 ,pp. : 1023-1036

Springer Publishing Company

Access to resources Recommend Favorite

Factors Affecting the Sexual Satisfaction of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

By Akkuş Yeliz  

Sexuality and Disability, Vol. 28, Iss. 4, 2010-12 ,pp. : 223-232

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Rheumatoid Arthritis by TNF-Blocking Agents

By  

International Archives of Allergy and Immunology, Vol. 127, Iss. 1, 2002-02 ,pp. : 10-14

Karger

Access to resources Recommend Favorite